A new Drug Has Been Invented By Researchers Who Think It Can Treat Pancreatic Cancer
A new drug has been invented for the treatment of pancreatic cancer. The drug has also in the initial results showed promise. Therapies used for curing pancreatic cancer are all based on causing damaging to the DNA but Pancreatic Cancer’s ability to repair that damage to the DNA make the therapies ineffective.
Meredith Morgan who had led the research by laboratory researchers of Rogel Cancer Center have found that AZD1775 was what was preventing the cancer from shielding itself against the radiation effects while the normal cells would be unaffected. One of the study authors, Kyle Cuneo felt that if there was a way to disable the response to DNA damage in cells of pancreatic cancer they may be able to eliminate the resistance to the treatment and also sensitize the cancer cells to the effects of both chemotherapy and radiation.
The trial which involved 43 patients who had advanced cancer, the patients were given AZD1775 with the gemcitabine and radiation. The aim of this was to figure out the amount of dose of AZD1775 which can be tolerable in the combination.
In that process, the researches could find better results of survival through this combination. Pancreatic Cancer has a survival rate of 9% in five years as it spreads to distant parts of the body. Ted Lawrance who was a senior author in the research feels that if they have to cure the cancer, they’ll need local therapy as well as an effective systematic treatment and according to their data AZD1775 can do both effectively.
It is being said that further studies will be needed, although the adding of AZD1775 was tolerated reasonably well and survival of 12-14 months was found. The overall survival was found to be an average of 22 months.